A Novel Mechanism That Changes HIV Prevention
Lenacapavir works by targeting the HIV capsid protein — a structural component essential to multiple stages of the viral replication cycle — making it the first drug in a new antiretroviral class. Unlike integrase inhibitors, reverse transcriptase inhibitors, or protease inhibitors, lenacapavir’s capsid-targeting mechanism means it has no pre-existing cross-resistance with any licensed antiretroviral agent, a property that carries significant implications for both treatment and prevention.
The pharmacokinetic profile of lenacapavir is what enables its twice-yearly subcutaneous injection schedule. After a single injection, the drug maintains plasma concentrations above the protein-adjusted 95% inhibitory concentration for at least six months, providing a sustained pharmacological shield against HIV acquisition. This is a fundamentally different approach from daily oral tenofovir-based PrEP or even the every-two-month intramuscular cabotegravir regimen from ViiV Healthcare.
HIV capsid inhibitors target the conical protein shell (capsid) that surrounds the viral RNA genome. The HIV capsid plays critical roles in nuclear import, reverse transcription, and viral assembly. Lenacapavir disrupts all of these processes simultaneously, distinguishing it mechanistically from every other licensed antiretroviral drug class and eliminating the risk of cross-resistance with existing agents.
The subcutaneous route of administration — into the fat tissue of the abdomen — is also notable. It avoids the requirement for intramuscular injection by a healthcare professional that cabotegravir demands, potentially enabling a broader range of administration settings including pharmacies and community health workers, depending on national regulatory frameworks. According to WHO, expanding the diversity of administration settings is a central strategy for reaching populations most at risk of HIV acquisition globally.
Lenacapavir is a first-in-class HIV capsid inhibitor that disrupts the HIV capsid protein at multiple stages of the viral replication cycle, has no cross-resistance with any existing antiretroviral drug class, and is administered as a subcutaneous injection once every six months for HIV pre-exposure prophylaxis.
PURPOSE Trials: Efficacy Data That Stopped Trials Early
The PURPOSE clinical programme produced two pivotal results that independent data monitoring committees deemed so compelling that both trials were unblinded early — a rare occurrence in late-stage pharmaceutical research. PURPOSE 1, conducted in cisgender women in sub-Saharan Africa, recorded zero HIV infections in the lenacapavir arm, translating to 100% efficacy. PURPOSE 2, which enrolled a broader global population including men who have sex with men, transgender women, transgender men, and gender non-binary individuals across multiple continents, demonstrated 96% efficacy compared with background HIV incidence rates.
“Zero HIV infections in the lenacapavir arm of PURPOSE 1 — a result so striking that the independent data monitoring committee recommended early unblinding on ethical grounds.”
The populations enrolled in the PURPOSE trials reflect a deliberate strategy to generate efficacy evidence across the full spectrum of individuals at elevated HIV risk. Sub-Saharan Africa carries a disproportionate share of the global HIV burden, with UNAIDS reporting that the region accounts for more than two-thirds of all people living with HIV globally. Cisgender adolescent girls and young women in eastern and southern Africa face particularly high incidence rates, making PURPOSE 1’s 100% efficacy finding especially significant for public health planning.
The diversity of PURPOSE 2’s enrolled population is particularly important for regulatory strategy. By demonstrating efficacy across multiple genders, sexual orientations, and geographic regions, Gilead has built an evidence base that supports a broad label — one that encompasses the full range of individuals for whom PrEP is indicated, as defined by guidelines from bodies including the US CDC. A broad label maximises the commercial addressable market and, critically, the public health reach of the intervention.
The PURPOSE 1 trial of twice-yearly lenacapavir for HIV PrEP, conducted in cisgender women in sub-Saharan Africa, recorded zero HIV infections in the lenacapavir arm — a 100% efficacy result — leading to early unblinding on the recommendation of the independent data monitoring committee.
Explore the full lenacapavir patent landscape and PURPOSE trial intelligence in PatSnap Eureka.
Search Lenacapavir Patents in PatSnap Eureka →The Long-Acting PrEP Competitive Landscape
The long-acting HIV PrEP market is transitioning from a single-agent landscape — dominated by daily oral tenofovir alafenamide/emtricitabine and tenofovir disoproxil fumarate/emtricitabine — to a multi-modality arena where injection frequency, mechanism of action, and access strategy differentiate products. Lenacapavir’s twice-yearly schedule positions it as the most infrequent-dosing option currently in or near regulatory approval.
Cabotegravir (Apretude) — ViiV Healthcare
ViiV Healthcare’s cabotegravir, marketed as Apretude, is the only long-acting injectable PrEP agent with full regulatory approval as of mid-2025. Administered as an intramuscular injection every two months — requiring eight clinic visits per year — it demonstrated superiority over daily oral tenofovir disoproxil fumarate/emtricitabine in the HPTN 083 and HPTN 084 trials. Lenacapavir’s twice-yearly schedule requires only two injections per year, a four-fold reduction in injection frequency that represents a meaningful adherence and healthcare-system burden advantage.
Broadly Neutralising Antibodies and the Emerging Pipeline
Beyond small molecules, the long-acting HIV prevention pipeline includes broadly neutralising antibodies (bNAbs) such as VRC01 and N6LS, under investigation by the NIH and academic partners in the Antibody Mediated Prevention (AMP) trials. While VRC01 did not demonstrate sufficient efficacy across the full range of HIV subtypes circulating in the AMP trials, next-generation bNAb combinations and bispecific antibodies remain active areas of research. Islatravir, Merck’s nucleoside reverse transcriptase translocation inhibitor (NRTTI) previously investigated as a monthly oral or implant-based PrEP agent, faced setbacks due to CD4 cell count declines observed in clinical trials, leaving lenacapavir as the dominant long-acting small-molecule candidate.
Merck’s islatravir — once considered a promising monthly oral or implant-based PrEP agent — was deprioritised for PrEP after clinical trials observed unexpected CD4 T-cell count declines in participants. This setback removed the most credible small-molecule competitor to lenacapavir in the long-acting PrEP space, strengthening Gilead’s competitive position ahead of regulatory decisions.
Cabotegravir (Apretude), developed by ViiV Healthcare, requires eight intramuscular injections per year for HIV PrEP, compared with two subcutaneous injections per year for lenacapavir — a four-fold difference in injection frequency that constitutes a significant adherence and healthcare system advantage for lenacapavir.
Patent Strategy, Licensing, and Global Access
Gilead Sciences has pursued a dual-track strategy for lenacapavir: robust patent protection in high-income markets to recover the investment in drug development and clinical trials, combined with voluntary licensing agreements that enable generic manufacturers to produce and supply lenacapavir affordably in low- and middle-income countries (LMICs). The voluntary licensing programme covers more than 120 countries — the majority of those with the highest HIV burden — and represents a significant departure from the more restrictive access strategies historically associated with novel antiretrovirals.
The patent landscape for lenacapavir encompasses composition-of-matter patents covering the active pharmaceutical ingredient, formulation patents protecting the specific subcutaneous depot formulation that enables the six-month dosing interval, and method-of-use patents covering the PrEP indication. Composition-of-matter protection is typically the most durable, with expiry dates in major markets extending into the 2030s. Formulation patents add additional layers of exclusivity that could complicate generic entry even in markets not covered by voluntary licences.
Analyse Gilead’s lenacapavir patent portfolio — composition, formulation, and method-of-use claims — with PatSnap Eureka.
Explore Lenacapavir Patent Data in PatSnap Eureka →The voluntary licensing approach has precedent in Gilead’s HIV treatment portfolio — the company employed similar strategies for tenofovir-based regimens through the Medicines Patent Pool, an initiative supported by WHO. For lenacapavir PrEP, the scale of the licensing programme — covering over 120 countries — reflects both the severity of the HIV epidemic in LMICs and the reputational and regulatory incentive for Gilead to demonstrate a credible access commitment ahead of regulatory reviews in major markets.
Gilead Sciences has entered voluntary licensing agreements with generic manufacturers to enable affordable production and supply of lenacapavir for HIV PrEP in more than 120 low- and middle-income countries, covering the majority of nations with the highest HIV burden globally.
Regulatory Pathway and the Road to Approval
Following the landmark PURPOSE trial results, Gilead Sciences submitted regulatory applications for lenacapavir as PrEP to the US FDA, the European Medicines Agency (EMA), and regulators in multiple high-burden countries. The FDA granted Priority Review designation to the lenacapavir PrEP application, reflecting the agency’s assessment of the unmet medical need and the strength of the clinical evidence. Priority Review shortens the standard review period from twelve months to six months, accelerating the potential approval timeline.
The regulatory strategy for lenacapavir PrEP benefits from the drug’s existing approval for HIV treatment — lenacapavir received FDA approval for treatment of multidrug-resistant HIV in adults in 2022, under the brand name Sunlenca. This prior approval means that the safety database for lenacapavir is already substantial, and regulators have established familiarity with the drug’s pharmacology, manufacturing, and safety profile. The PrEP application is therefore primarily a matter of demonstrating efficacy in HIV-negative individuals — which the PURPOSE trials have done decisively.
Beyond the United States and Europe, regulatory submissions in sub-Saharan African countries and other high-burden regions are critical to realising the public health impact of lenacapavir PrEP. Regulatory bodies including the South African Health Products Regulatory Authority (SAHPRA) and the WHO Prequalification Programme — which enables procurement by UNICEF, the Global Fund, and PEPFAR — are key gatekeepers for access in LMICs. WHO prequalification, in particular, is often a prerequisite for large-scale procurement by international health financing mechanisms, according to guidance published by the WHO.
The FDA’s Priority Review designation, granted to Gilead’s lenacapavir PrEP application, reduces the standard review period from twelve months to six months. It is awarded when a drug addresses an unmet medical need for a serious condition. For lenacapavir, this designation reflects both the scale of the HIV epidemic and the absence of any twice-yearly prevention option prior to this application.
The competitive implications of regulatory timing are significant. If lenacapavir receives FDA approval for PrEP before cabotegravir’s label is updated or extended, Gilead will have a window to establish formulary positions, negotiate with payers, and build prescriber familiarity with the twice-yearly regimen. In LMICs, the race to WHO prequalification and national registration determines which product reaches public health programmes first — and first-mover advantages in procurement relationships can persist for years. Patent intelligence tools such as PatSnap Eureka enable R&D teams and business development professionals to monitor competitor filings, track regulatory milestones, and identify white space in the long-acting HIV prevention patent landscape.